| HOME >> BIOLOGY >> TECHNOLOGY |
NEW YORK, April 24 /PRNewswire/ -- The Children's Hospital Foundation, the parent company of The Children's Hospital of Philadelphia(R), and Royalty Pharma announced today that the Foundation has sold its worldwide royalty interest in respect of sales of RotaTeq(R) from and after October 1, 2007, to Royalty Pharma for $182 million in cash.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061026/RPLOGO )
"With the addition of this royalty on RotaTeq(R), we further our strategy of building a highly diversified portfolio of royalty interests on leading biopharmaceutical products. We are pleased to add the first vaccine to complement our royalties on products that treat a wide range of diseases, including cancer, rheumatoid arthritis and other autoimmune disorders, AIDS/HIV and neuropathic pain," said Pablo Legorreta, Chief Executive Officer of Royalty Pharma. "More important, we are partnering with the world's best research hospitals, universities and biopharmaceutical companies, and providing them with critical sources of financing that they can employ in further research and development endeavors. This will result, hopefully, in continued innovation and therapeutic alternatives for patients."
"CHOP will use this money in the continual pursuit of advancing science to benefit children," said Steven M. Altschuler, MD, President and Chief Executive Officer, The Children's Hospital of Philadelphia(R).
RotaTeq(R) is a live, oral pentavalent vaccine indicated for the
prevention of rotavirus gastroenteritis. RotaTeq(R) was approved by the
United States Food and Drug Administration in February 2006, has been
approved in 70 other countries and has launched in 42 of these countries.
It is marketed by Merck & Co. Inc. RotaTeq(R) was created as a result of
research jointly performed by The Children's Hospital of Philadelphia(R)
and The Wistar Institute, Philadelphia, PA.
'/>"/>
| SOURCE Royalty Pharma Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
2. Drug Royalty Corporation Changes Its Name to DRI Capital
3. Cowen Group, Inc. and Cowen Healthcare Royalty Partners Announce Expansion of Royalty Investment Team
4. Cowen Group, Inc. and Cowen Healthcare Royalty Partners Announce Expansion of Royalty Investment Team
5. Antibody Engineering Company F-Star Buys Back Royalty Obligations
6. CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
7. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
8. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
11. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |